CA2709153A1 - Impaired wound healing compositions and treatments - Google Patents

Impaired wound healing compositions and treatments Download PDF

Info

Publication number
CA2709153A1
CA2709153A1 CA2709153A CA2709153A CA2709153A1 CA 2709153 A1 CA2709153 A1 CA 2709153A1 CA 2709153 A CA2709153 A CA 2709153A CA 2709153 A CA2709153 A CA 2709153A CA 2709153 A1 CA2709153 A1 CA 2709153A1
Authority
CA
Canada
Prior art keywords
connexin
seq
wound
agent
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2709153A
Other languages
English (en)
French (fr)
Inventor
Bradford J. Duft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inflammx Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2709153A1 publication Critical patent/CA2709153A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2709153A 2007-12-11 2008-12-11 Impaired wound healing compositions and treatments Abandoned CA2709153A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US726207P 2007-12-11 2007-12-11
US61/007,262 2007-12-11
PCT/US2008/013656 WO2009075882A2 (en) 2007-12-11 2008-12-11 Impaired wound healing compositions and treatments

Publications (1)

Publication Number Publication Date
CA2709153A1 true CA2709153A1 (en) 2009-06-18

Family

ID=40626592

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2709153A Abandoned CA2709153A1 (en) 2007-12-11 2008-12-11 Impaired wound healing compositions and treatments

Country Status (8)

Country Link
US (1) US20100279921A1 (https=)
EP (1) EP2245158A2 (https=)
JP (3) JP2011506447A (https=)
CN (2) CN101970663A (https=)
AU (2) AU2008335718A1 (https=)
CA (1) CA2709153A1 (https=)
WO (1) WO2009075882A2 (https=)
ZA (1) ZA201004998B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102073629B1 (ko) 2005-02-03 2020-02-05 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
EP2543377A1 (en) 2006-12-11 2013-01-09 Coda Therapeutics, INC. Anticonnexin polynucleotides as impaired wound healing compositions
JP2011507859A (ja) * 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 外科的癒着の治療のための抗コネキシンポリヌクレオチドの使用
WO2009085268A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
WO2009085271A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions
US20110092449A1 (en) * 2007-12-21 2011-04-21 Bradford James Duft Treatment of fibrotic conditions
EP2252320A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides and peptides for the treatment of abnormal or excessive scars
US8975237B2 (en) 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
CA2710386A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Improved medical devices
DK2819682T3 (en) 2012-03-01 2017-08-21 Firststring Res Inc TOPICAL GELLS CONTAINING ALPHA-CONNEXIN C-TERMINAL (ACT) PEPTIDES
US20140031753A1 (en) * 2012-07-25 2014-01-30 Neil T. Winthrop Thoracostomy devices and methods of use
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
CA2940648A1 (en) * 2014-02-25 2015-09-03 Coda Therapeutics, Inc. Treatment of resistant lesions
CN107109410B (zh) 2014-08-22 2021-11-02 奥克兰联合服务有限公司 通道调节剂
US9885042B2 (en) * 2015-01-20 2018-02-06 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
CA3061738A1 (en) 2017-04-28 2018-11-01 Auckland Uniservices Limited Methods of treatment and novel constructs
CN109513037B (zh) * 2018-11-14 2021-09-17 华中科技大学同济医学院附属协和医院 一种负载介孔生物玻璃的小肠粘膜下层创面敷料
WO2021119198A1 (en) * 2019-12-09 2021-06-17 Cage Bio, Inc. Topical delivery of rna interference agents using ionic liquid
CN111214694B (zh) * 2020-03-31 2022-04-22 山东大鱼生物技术有限公司 一种具有止血和加速伤口愈合功能的敷料及其制备方法
MX2023004631A (es) 2020-10-22 2023-07-20 Xequel Bio Inc Formulaciones peptidicas y usos oftalmicos de las mismas.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0539594Y2 (https=) * 1988-08-05 1993-10-07
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
EP2314321B1 (en) * 1999-01-27 2014-06-04 Coda Therapeutics, Inc. Formulations comprising antisense nucleotides to connexins
US7250397B2 (en) * 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
CN1638790A (zh) * 2002-01-29 2005-07-13 Wyeth公司 用于调节连接蛋白半通道的组合物和方法
RU2438696C2 (ru) * 2004-12-21 2012-01-10 Маск Фаундейшн Фор Рисерч Дивелопмент Композиции и способы, используемые для ускорения заживления ран и регенерации тканей
KR102073629B1 (ko) * 2005-02-03 2020-02-05 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
AU2007319811A1 (en) * 2006-11-15 2008-05-22 Coda Therapeutics, Inc. Improved methods and compositions for wound healing
EP2543377A1 (en) * 2006-12-11 2013-01-09 Coda Therapeutics, INC. Anticonnexin polynucleotides as impaired wound healing compositions
WO2009075881A2 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
WO2009085271A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions
WO2009085268A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
US20110092449A1 (en) * 2007-12-21 2011-04-21 Bradford James Duft Treatment of fibrotic conditions
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
CA2711635A1 (en) * 2008-01-07 2009-08-06 Coda Therapeutics, Inc. Wound healing compositions and treatments

Also Published As

Publication number Publication date
AU2015200904A1 (en) 2015-03-12
ZA201004998B (en) 2011-06-29
CN101970663A (zh) 2011-02-09
AU2008335718A1 (en) 2009-06-18
JP2014144976A (ja) 2014-08-14
US20100279921A1 (en) 2010-11-04
CN102920996A (zh) 2013-02-13
JP2016135799A (ja) 2016-07-28
WO2009075882A9 (en) 2009-09-17
JP2011506447A (ja) 2011-03-03
EP2245158A2 (en) 2010-11-03
WO2009075882A2 (en) 2009-06-18
WO2009075882A3 (en) 2009-07-30

Similar Documents

Publication Publication Date Title
US20100279921A1 (en) Impaired wound healing compositions and treatments
AU2018200326B2 (en) Improved methods and compositions for wound healing
US9637745B2 (en) Impaired wound healing compositions and treatments
US20110038920A1 (en) Wound healing compositions and treatments
US20130184220A1 (en) Treatment of abnormal or excessive scars
US20180028468A1 (en) Sustained release drug delivery devices
AU2014204482B2 (en) Anticonnexin polynucleotides as impaired wound healing compositions
HK1136213B (en) Anticonnexin polynucleotides as impaired wound healing compositions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131209

FZDE Discontinued

Effective date: 20161212